Search - tctmd.com

Displaying 501 - 520 of 687

Sort: Relevancy | Date

Presentation TCT 2017

The Compelling Saga of Stroke after TAVR: Key Messages From NeuroARC

Presenter: Michael J. Reardon, Didier Tchetche, Alexandra J. Lansky

October 31, 2017

Presentation TCT 2017

Musings on TMVR Patient Selection Criteria to Date, and Which Patients Should Be Put in TMVR Trials Rather Than Treated Clinically With Current Devices

Presenter: Howard C. Herrmann, Michael J. Mack

October 31, 2017

Presentation TCT 2017

Emerging TMVR 5: Mitraltech - Device Description, Critical Appraisal, and Development Plans

Presenter: Howard C. Herrmann, Michael J. Mack, Francesco Maisano

October 31, 2017

Presentation TCT 2017

Emerging TMVR 4: Corona Valve With Amend Ring - Device Description, Critical Appraisal, and Development Plans

Presenter: Howard C. Herrmann, Michael J. Mack, David Meerkin

October 31, 2017

Presentation TCT 2017

Emerging TMVR 3: M-Dock - Device Description, Critical Appraisal, and Development Plans

Presenter: Howard C. Herrmann, Michael J. Mack, Maurice Buchbinder

October 31, 2017

Presentation TCT 2017

Emerging TMVR 2: 4C - Device Description, Critical Appraisal, and Development Plans

Presenter: Howard C. Herrmann, Michael J. Mack, Philippe Genereux

October 31, 2017

Presentation TCT 2017

Established TMVR 6: Caisson - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Mathew Williams

October 31, 2017

Presentation TCT 2017

Established TMVR 5: Highlife - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Nicolo Piazza

October 31, 2017

Presentation TCT 2017

Established TMVR 4: Intrepid - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Vinayak Bapat

October 31, 2017

Presentation TCT 2017

Established TMVR 3: Tendyne - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, David W.M. Muller

October 31, 2017

Presentation TCT 2017

Established TMVR 2: Tiara - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Anson Cheung

October 31, 2017

Presentation TCT 2017

Established TMVR 1: Cardiaq - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, James B. Hermiller Jr.

October 31, 2017

Presentation TCT 2017

Keynote Address: Grand Summary of the Vast TMVR Landscape - Differentiating Features and Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Bernard Prendergast

October 31, 2017

Presentation TCT 2017

TCT 36: Delayed Coronary Obstruction After Transcatheter Aortic Valve Replacement

Presenter: Reginald I. Low, Michael J. Rinaldi, Richard Jabbour

October 31, 2017

Presentation TCT 2017

TCT 36: Cerebral Embolic Protection During Transfemoral Aortic Valve Replacement Reduces Death and Stroke Compared to Unprotected Procedure in All Subgroups

Presenter: Reginald I. Low, Michael J. Rinaldi, Julia Seeger

October 31, 2017

Presentation TCT 2017

TCT 34: Prediction of Acute Kidney Injury After TAVR by New Biomarkers

Presenter: Reginald I. Low, Michael J. Rinaldi, Mani Arsalan, MD

October 31, 2017

Presentation TCT 2017

TCT 33: Effect of Percutaneous Paravalvular Leak Closure on Hemolysis

Presenter: Reginald I. Low, Michael J. Rinaldi, Sidakpal Panaich, MD

October 31, 2017

Presentation TCT 2017

Futuristic and Novel #2: Using Artificial Intelligence (Machine Learning) to Direct Acquisition and Interpretation of Echocardiograms Improving Access and Quality of Valve Disease Diagnosis

Presenter: Robert O. Bonow, Michael J. Mack, Randolph P. Martin

October 30, 2017

Presentation TCT 2017

Do the PIONEER and RE-DUAL Results Alter LAA Closure Decisions?

Presenter: William A. Gray, Vivek Y. Reddy, C. Michael Gibson

October 30, 2017

Presentation TCT 2017

Futuristic and Novel #1: The Promise of Tissue Engineered Bioprosthetic Heart Valves (Both Surgical and Transcatheter) is Within Reach

Presenter: Robert O. Bonow, Michael J. Mack, Maximilian Y Emmert

October 30, 2017

Advertisement

The Compelling Saga of Stroke after TAVR: Key Messages From NeuroARC

Musings on TMVR Patient Selection Criteria to Date, and Which Patients Should Be Put in TMVR Trials Rather Than Treated Clinically With Current Devices

Emerging TMVR 5: Mitraltech - Device Description, Critical Appraisal, and Development Plans

Emerging TMVR 4: Corona Valve With Amend Ring - Device Description, Critical Appraisal, and Development Plans

Emerging TMVR 3: M-Dock - Device Description, Critical Appraisal, and Development Plans

Emerging TMVR 2: 4C - Device Description, Critical Appraisal, and Development Plans

Established TMVR 6: Caisson - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Established TMVR 5: Highlife - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Established TMVR 4: Intrepid - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Established TMVR 3: Tendyne - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Established TMVR 2: Tiara - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Established TMVR 1: Cardiaq - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Keynote Address: Grand Summary of the Vast TMVR Landscape - Differentiating Features and Outcomes

TCT 36: Delayed Coronary Obstruction After Transcatheter Aortic Valve Replacement

TCT 36: Cerebral Embolic Protection During Transfemoral Aortic Valve Replacement Reduces Death and Stroke Compared to Unprotected Procedure in All Subgroups

TCT 34: Prediction of Acute Kidney Injury After TAVR by New Biomarkers

TCT 33: Effect of Percutaneous Paravalvular Leak Closure on Hemolysis

Futuristic and Novel #2: Using Artificial Intelligence (Machine Learning) to Direct Acquisition and Interpretation of Echocardiograms Improving Access and Quality of Valve Disease Diagnosis

Do the PIONEER and RE-DUAL Results Alter LAA Closure Decisions?

Futuristic and Novel #1: The Promise of Tissue Engineered Bioprosthetic Heart Valves (Both Surgical and Transcatheter) is Within Reach

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content